317 related articles for article (PubMed ID: 10779805)
1. Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+ CTL.
Bergmann-Leitner ES; Abrams SI
J Immunol; 2000 May; 164(9):4941-54. PubMed ID: 10779805
[TBL] [Abstract][Full Text] [Related]
2. Influence of interferon gamma on modulation of Fas expression by human colon carcinoma cells and their subsequent sensitivity to antigen-specific CD8+ cytotoxic T lymphocyte attack.
Bergmann-Leitner ES; Abrams SI
Cancer Immunol Immunother; 2000 Jul; 49(4-5):193-207. PubMed ID: 10941902
[TBL] [Abstract][Full Text] [Related]
3. Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes.
Bergmann-Leitner ES; Abrams SI
Cancer Immunol Immunother; 2001 Nov; 50(9):445-55. PubMed ID: 11761438
[TBL] [Abstract][Full Text] [Related]
4. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
[TBL] [Abstract][Full Text] [Related]
5. Treatment of melanoma with 5-fluorouracil or dacarbazine in vitro sensitizes cells to antigen-specific CTL lysis through perforin/granzyme- and Fas-mediated pathways.
Yang S; Haluska FG
J Immunol; 2004 Apr; 172(7):4599-608. PubMed ID: 15034078
[TBL] [Abstract][Full Text] [Related]
6. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N; Brooks AD; Carter CR; Back TC; Parsoneault EM; Smyth MJ; Wiltrout RH; Sayers TJ
J Immunol; 2002 Apr; 168(7):3484-92. PubMed ID: 11907109
[TBL] [Abstract][Full Text] [Related]
7. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy.
Chakraborty M; Abrams SI; Camphausen K; Liu K; Scott T; Coleman CN; Hodge JW
J Immunol; 2003 Jun; 170(12):6338-47. PubMed ID: 12794167
[TBL] [Abstract][Full Text] [Related]
8. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases.
Caldwell SA; Ryan MH; McDuffie E; Abrams SI
J Immunol; 2003 Sep; 171(5):2402-12. PubMed ID: 12928387
[TBL] [Abstract][Full Text] [Related]
9. Expression in cytotoxic T lymphocytes of a single-chain anti-carcinoembryonic antigen antibody. Redirected Fas ligand-mediated lysis of colon carcinoma.
Darcy PK; Kershaw MH; Trapani JA; Smyth MJ
Eur J Immunol; 1998 May; 28(5):1663-72. PubMed ID: 9603473
[TBL] [Abstract][Full Text] [Related]
10. Bcl-2 protects against Fas-based but not perforin-based T cell-mediated cytolysis.
Lee RK; Spielman J; Podack ER
Int Immunol; 1996 Jul; 8(7):991-1000. PubMed ID: 8757944
[TBL] [Abstract][Full Text] [Related]
11. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL.
Darcy PK; Haynes NM; Snook MB; Trapani JA; Cerruti L; Jane SM; Smyth MJ
J Immunol; 2000 Apr; 164(7):3705-12. PubMed ID: 10725729
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the Fas ligand/Fas-dependent apoptosis of antiretroviral, class I MHC tetramer-defined, CD8+ CTL by in vivo retrovirus-infected cells.
Rich RF; Green WR
J Immunol; 2002 Mar; 168(6):2751-8. PubMed ID: 11884442
[TBL] [Abstract][Full Text] [Related]
13. Disparate cytotoxic activity of nickel-specific CD8+ and CD4+ T cell subsets against keratinocytes.
Traidl C; Sebastiani S; Albanesi C; Merk HF; Puddu P; Girolomoni G; Cavani A
J Immunol; 2000 Sep; 165(6):3058-64. PubMed ID: 10975816
[TBL] [Abstract][Full Text] [Related]
14. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
[TBL] [Abstract][Full Text] [Related]
15. Positive and negative consequences of soluble Fas ligand produced by an antigen-specific CD4(+) T cell response in human carcinoma immune interactions.
Bergmann-Leitner ES; Abrams SI
Cell Immunol; 2001 Apr; 209(1):49-62. PubMed ID: 11414736
[TBL] [Abstract][Full Text] [Related]
16. Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin- and Fas-based lytic pathways in cell-mediated cytotoxicity.
Kataoka T; Shinohara N; Takayama H; Takaku K; Kondo S; Yonehara S; Nagai K
J Immunol; 1996 May; 156(10):3678-86. PubMed ID: 8621902
[TBL] [Abstract][Full Text] [Related]
17. ECH, an epoxycyclohexenone derivative that specifically inhibits Fas ligand-dependent apoptosis in CTL-mediated cytotoxicity.
Mitsui T; Miyake Y; Kakeya H; Osada H; Kataoka T
J Immunol; 2004 Mar; 172(6):3428-36. PubMed ID: 15004142
[TBL] [Abstract][Full Text] [Related]
18. Anti-idiotype antibody induced cellular immunity in mice transgenic for human carcinoembryonic antigen.
Saha A; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
Immunology; 2006 Aug; 118(4):483-96. PubMed ID: 16895556
[TBL] [Abstract][Full Text] [Related]
19. IFN-gamma promotes Fas ligand- and perforin-mediated liver cell destruction by cytotoxic CD8 T cells.
Roth E; Pircher H
J Immunol; 2004 Feb; 172(3):1588-94. PubMed ID: 14734739
[TBL] [Abstract][Full Text] [Related]
20. Essential roles of perforin in antigen-specific cytotoxicity mediated by human CD4+ T lymphocytes: analysis using the combination of hereditary perforin-deficient effector cells and Fas-deficient target cells.
Yanai F; Ishii E; Kojima K; Hasegawa A; Azuma T; Hirose S; Suga N; Mitsudome A; Zaitsu M; Ishida Y; Shirakata Y; Sayama K; Hashimoto K; Yasukawa M
J Immunol; 2003 Feb; 170(4):2205-13. PubMed ID: 12574394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
